Fertility Preservation Pathways Before Emergency Organ Transplantation

Abstract

Emergency organ transplantation can be lifesaving, yet the associated disease process, gonadotoxic treatment, critical illness, and time-sensitive surgical pathway may threaten future reproductive potential. Fertility preservation should therefore be considered early, even when transplantation is being evaluated under urgent or unstable conditions. This review outlines the biological mechanisms of reproductive injury, patient-specific risk assessment, diagnostic evaluation, preservation options, and practical coordination between transplant, reproductive medicine, oncology, endocrinology, and critical care teams. Established approaches include sperm cryopreservation, oocyte and embryo vitrification, ovarian tissue cryopreservation, testicular tissue cryopreservation in selected patients, and gonadal tissue or gamete donation when autologous strategies are not feasible. The choice depends on age, pubertal status, sex assigned at birth, urgency of transplantation, physiological stability, anticipated immunosuppression, underlying disease, and reproductive goals. Recent advances in in vitro maturation, ovarian tissue transplantation, fertility-sparing surgery, and laboratory cryobiology are expanding options, although access, safety, and long-term outcome data remain uneven. A structured fertility pathway should be integrated into transplant triage without delaying medically necessary transplantation.

Introduction

Organ transplantation increasingly provides long-term survival for patients with advanced hepatic, renal, cardiac, pulmonary, and multisystem disease. Many recipients are children, adolescents, or adults of reproductive age who may wish to conceive after recovery. Fertility counseling is often deferred because the immediate priority is organ failure, infection control, hemodynamic stabilization, or transplantation. Nevertheless, reproductive injury may occur before the transplant through chronic disease, acute systemic inflammation, malnutrition, endocrine dysfunction, surgery, medications, or exposure to cytotoxic therapy. Additional injury may develop after transplantation through immunosuppressive treatment, graft dysfunction, infections, metabolic disease, and delayed recovery.

Fertility preservation is consequently a time-critical component of comprehensive transplant care. The objective is not merely to store gametes or tissue, but to provide individualized counseling that explains the probability of reproductive impairment, realistic preservation success, potential effects of pregnancy on the graft, and the ethical and financial implications of treatment. Referral to reproductive specialists should occur at the earliest feasible point, ideally during transplant evaluation or immediately after recognition of a treatment likely to compromise gonadal function.

Epidemiology / Disease Burden

The burden of impaired fertility in patients with organ failure is difficult to quantify because studies use different definitions and many patients are never evaluated. Chronic kidney disease is associated with hypothalamic-pituitary-gonadal dysfunction, menstrual irregularity, reduced testosterone, erectile dysfunction, and impaired spermatogenesis. Advanced liver disease may produce hypogonadism through altered steroid metabolism, hyperprolactinemia, malnutrition, and systemic illness. Heart failure and pulmonary disease can reduce fertility through endocrine disruption, poor functional status, vascular disease, and medication exposure. In children and adolescents, severe illness may interrupt pubertal progression and compromise the future germ cell reserve.

Transplantation may restore endocrine function in some recipients, but recovery is not universal. Long-term immunosuppression, chronic graft dysfunction, obesity, diabetes, vascular complications, and recurrent disease may continue to affect reproductive health. Patients who undergo transplantation after cancer treatment or hematopoietic cell transplantation may face particularly high risks because alkylating agents, radiation, and conditioning regimens can cause permanent ovarian or testicular failure. The expanding survival of these populations makes fertility preservation a quality-of-life and survivorship priority rather than an optional service.

Pathophysiology

Gonadal injury results from several interacting mechanisms. In the ovary, depletion or damage of primordial follicles reduces ovarian reserve and may lead to premature ovarian insufficiency. Cytotoxic agents can induce follicular apoptosis, stromal fibrosis, vascular injury, and disruption of the theca and granulosa cell compartments. Pelvic or total-body irradiation may damage both follicles and uterine tissue. In males, chemotherapy and radiation may injure spermatogonial stem cells, Sertoli cells, Leydig cells, and the testicular microvasculature. The severity depends on cumulative dose, drug class, treatment field, age, and baseline gonadal reserve.

Critical illness can suppress reproductive signaling through inflammatory cytokines, increased cortisol, altered leptin signaling, and hypothalamic-pituitary dysfunction. Uremia, hepatic dysfunction, malnutrition, and iron overload may further impair gonadal function. Surgical stress and prolonged hospitalization can temporarily suppress fertility, while ischemia, thrombosis, or direct surgical injury may produce permanent damage. After transplantation, corticosteroids and other immunosuppressants may affect gonadal hormones, sexual function, glucose metabolism, and pregnancy safety. These mechanisms explain why preservation planning must account for the entire treatment trajectory rather than a single drug or procedure.

Risk Factors

Important risk factors include advanced age, diminished ovarian reserve, prior chemotherapy or radiotherapy, hematologic malignancy, pelvic surgery, testicular disease, cryptorchidism, severe systemic inflammation, renal or hepatic failure, endocrine disorders, malnutrition, and prolonged critical illness. In females, ovarian reserve is influenced by age, antral follicle count, anti-Müllerian hormone concentration, and prior gonadotoxic exposure. In males, baseline semen quality, testicular volume, endocrine status, and history of infertility help determine the likelihood of obtaining usable sperm.

Urgency is itself a major risk factor because conventional ovarian stimulation often requires approximately two weeks, whereas emergency transplantation may need to occur within days or hours. Hemodynamic instability, coagulopathy, infection, inability to tolerate anesthesia, and contraindications to hormonal stimulation can restrict available options. Ethical and logistical factors also matter, including lack of a partner, religious or legal restrictions, limited laboratory access, cost, and the patient’s ability to provide informed consent. For minors or incapacitated adults, preservation decisions should follow applicable consent laws while respecting the patient’s developing autonomy and previously expressed values.

Clinical Features

Reproductive impairment may be clinically silent. Female patients may present with irregular or absent menstruation, vasomotor symptoms, vaginal dryness, or delayed puberty, but normal cycles do not exclude reduced ovarian reserve. Male patients may have reduced libido, erectile dysfunction, reduced testicular volume, delayed puberty, or no symptoms despite severe oligospermia or azoospermia. In critically ill patients, these manifestations may be obscured by sedation, mechanical ventilation, organ failure, or acute treatment priorities.

Clinicians should ask about reproductive intentions, previous fertility, menstrual and pubertal history, pregnancies, contraception, sexual function, prior gonadotoxic treatment, and the possibility of future genetic parenthood. The discussion should be confidential, culturally sensitive, and inclusive of patients who may require donor gametes, gestational carriers, or non-genetic family-building strategies. Fertility counseling should not assume that a patient currently wants children; it should ensure that future choices are not unnecessarily removed.

Diagnosis

Assessment begins with a focused history and examination, followed by testing that can be completed without delaying urgent transplantation. For females, pregnancy testing, follicle-stimulating hormone, luteinizing hormone, estradiol, anti-Müllerian hormone, and transvaginal or transabdominal antral follicle assessment may help estimate reserve. Anti-Müllerian hormone and antral follicle count predict expected oocyte yield but do not independently guarantee natural conception or live birth. For males, at least one semen analysis is appropriate when clinically feasible, with repeat testing if the first specimen is abnormal. Follicle-stimulating hormone, luteinizing hormone, testosterone, inhibin B, and testicular examination may identify endocrine or primary testicular dysfunction.

Diagnostic interpretation must consider acute illness, medications, pubertal status, and pre-existing organ dysfunction. Ovarian reserve markers can be misleading during hormonal treatment or severe illness, and a single semen analysis may not represent long-term spermatogenic capacity. Genetic testing, infectious screening, and tissue-specific evaluations should be guided by the underlying disease and the proposed preservation procedure. Multidisciplinary review is essential when testing results conflict with the urgency or safety requirements of transplantation.

Treatment & Management

Sperm cryopreservation is usually the fastest and most established option for postpubertal males who can produce an ejaculate. Multiple samples should be collected when time and health permit. If ejaculation is impossible or sperm production is severely impaired, electroejaculation, microsurgical epididymal sperm aspiration, or testicular sperm extraction may be considered in specialized settings. Testicular tissue cryopreservation without mature sperm remains an investigational or highly selected approach, particularly in prepubertal boys, although maturation technologies are advancing.

For females, oocyte vitrification is standard practice for postpubertal patients who can safely undergo stimulation. Embryo cryopreservation is similarly established when a partner or donor sperm is available and the patient accepts embryo storage and its associated legal considerations. Random-start ovarian stimulation can begin at almost any phase of the menstrual cycle and may shorten delays. Letrozole-based stimulation may be considered when estrogen exposure is a concern, although the regimen must be tailored to the underlying disease and thrombotic risk.

Ovarian tissue cryopreservation is the principal established option for patients who cannot delay urgent treatment, prepubertal girls, and selected patients in whom stimulation is contraindicated. The cortex is removed laparoscopically or through an appropriate surgical approach, processed, and cryopreserved for possible later autotransplantation. Reimplantation has resulted in restoration of endocrine function and live births in selected patients, but it may be unsuitable when there is a substantial risk of reintroducing malignant cells. In such cases, research strategies involving isolated follicles, artificial ovaries, or in vitro maturation may become relevant.

Gonadal shielding, fertility-sparing surgery, and modification of treatment intensity may reduce reproductive injury when oncologically and medically safe. Gonadotropin-releasing hormone agonists have been studied as ovarian suppression during chemotherapy; they may reduce the risk of premature ovarian insufficiency in some settings, but they should not replace cryopreservation when established methods are feasible. After transplantation, pregnancy planning requires stable graft function, medication review, control of hypertension and diabetes, infection screening, and consultation with maternal-fetal medicine or a specialist familiar with transplant pregnancy.

Recent Advances / Emerging Therapies

Progress in cryobiology has improved survival of vitrified oocytes, embryos, and ovarian tissue. In vitro maturation may permit collection of immature oocytes when conventional stimulation is unsafe or too slow, although maturation rates and live-birth outcomes remain less predictable than with mature oocyte vitrification. Ovarian tissue transplantation techniques are being refined to improve revascularization, reduce ischemic follicle loss, and limit the risk of malignant cell reseeding. Cryopreservation of testicular tissue, spermatogonial stem cell isolation, and laboratory-based germ cell maturation are active areas of research for prepubertal patients.

Artificial ovary systems, three-dimensional follicle culture, tissue engineering, and targeted protection of germ cells may eventually provide alternatives for patients who cannot undergo tissue reimplantation. Advances in genetic and molecular profiling may improve prediction of gonadotoxicity and allow treatment selection based on individual susceptibility. However, these approaches require rigorous validation, long-term follow-up, regulatory oversight, and transparent communication that distinguishes experimental availability from established clinical care.

Guideline Recommendations

Major professional societies consistently recommend discussing fertility risk before gonadotoxic treatment and referring patients promptly to reproductive specialists. The discussion should occur at diagnosis or transplant evaluation, be documented in the medical record, and include the expected risk of infertility, available preservation methods, treatment timing, costs, alternatives, and future use of stored material. Preservation should not be withheld solely because the patient has advanced disease if the procedure can be performed safely and does not compromise lifesaving care.

Guideline-based practice supports sperm, oocyte, embryo, and ovarian tissue cryopreservation as established options in appropriate patients. Ovarian suppression may be offered as an adjunct rather than a substitute. For prepubertal children and experimental tissue-based approaches, clinicians should provide explicit counseling about uncertain efficacy and consider referral to experienced centers or ethically approved research programs. A transplant-specific plan should also address the timing of future pregnancy, teratogenic immunosuppressants, graft stability, genetic transmission of the underlying disease, contraception during recovery, and psychosocial support.

Conclusion

Fertility preservation before emergency organ transplantation requires rapid, individualized, and multidisciplinary decision-making. Reproductive injury may arise from the underlying organ failure, critical illness, surgery, cytotoxic exposure, or long-term immunosuppression, and it may occur even when symptoms are absent. Early counseling and parallel referral pathways allow clinicians to identify feasible options without unnecessarily delaying transplantation. Sperm, oocyte, embryo, and ovarian tissue cryopreservation provide established strategies, while testicular tissue, in vitro maturation, artificial ovary systems, and germ cell technologies continue to develop. Integrating reproductive medicine into transplant programs supports informed choice, improves survivorship planning, and recognizes future parenthood as an important component of patient-centered medical care.